5 Results for "

GIRK current activation

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "GIRK current activation" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-121685A
CAS No.: 1449686-84-3
Purity:  99.98%
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

Tipepidine hydrochloride reversibly inhibits dopamine (DA) D2 receptor-mediated GIRK currents (IDA(GIRK)) with an IC50 of 7.0 μM. Tipepidine hydrochloride subsequently activates VTA dopamine neuron . Tipepidine hydrochloride, a non-narcotic antitussive, exerts an antidepressant-like effect .
loading...
    loading...
Cat. No.: HY-121685
CAS No.: 5169-78-8
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

Tipepidine reversibly inhibits dopamine (DA) D2 receptor-mediated GIRK currents (IDA(GIRK)) with an IC50 of 7.0 μM. Tipepidine subsequently activates VTA dopamine neuron . Tipepidine, a non-narcotic antitussive, exerts an antidepressant-like effect .
loading...
    loading...
Cat. No.: HY-B2185
CAS No.: 14698-07-8
Tipepidine citrate is a non-narcotic antitussive agent. Tipepidine citrate reversibly inhibits dopamine D2 receptor-mediated GIRK current (IDA(GIRK)), thereby activating VTA dopamine neurons, with an IC50 of 7.0 μM for IDA(GIRK). Tipepidine activates AMPK. Tipepidine citrate has antidepressant-like effects. Tipepidine citrate enhances the analgesic effect of Carbamazepine (HY-B0246). Tipepidine citrate improves adipose tissue fibrosis and glucose intolerance in high-fat diet-induced obese mice .
loading...
    loading...
Cat. No.: HY-175556
Target:  

Dopamine Receptor

Research Areas:  

Neurological Disease

CNV-dopamine is a photoreleasable D2 receptor-selective agonist. CNV-dopamine activates D2 receptors and induces G protein-coupled inwardly rectifying potassium (GIRK) currents. CNV-dopamine is promising for research of disorders like Parkinson’s disease and addiction .
loading...
    loading...
Cat. No.: HY-187840
CAS No.: 194038-94-3
RBI257 is a selective dopamine D4R antagonist with a pKi of 8.42 for the hD4.4 receptor. RBI257 acts as a competitive antagonist at the hD4.4 receptor, blocking dopamine-stimulated G protein activation and GIRK current activation. RBI257 can be used for research on hypertension and schizophrenia .
loading...
    loading...